Selected article for: "active mers cov and acute sars cov respiratory syndrome coronavirus"
Author: Lin, Min-Han; Moses, David C.; Hsieh, Chih-Hua; Cheng, Shu-Chun; Chen, Yau-Hung; Sun, Chiao-Yin; Chou, Chi-Yuan
Title: Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes
  • Cord-id: 4yecwdlo
  • Document date: 2017_12_28
    • ID: 4yecwdlo
    Snippet: Severe acute respiratory syndrome coronavirus (SARS-CoV) emerged in southern China in late 2002 and caused a global outbreak with a fatality rate around 10% in 2003. Ten years later, a second highly pathogenic human CoV, MERS-CoV, emerged in the Middle East and has spread to other countries in Europe, North Africa, North America and Asia. As of November 2017, MERS-CoV had infected at least 2102 people with a fatality rate of about 35% globally, and hence there is an urgent need to identify antiv
    Document: Severe acute respiratory syndrome coronavirus (SARS-CoV) emerged in southern China in late 2002 and caused a global outbreak with a fatality rate around 10% in 2003. Ten years later, a second highly pathogenic human CoV, MERS-CoV, emerged in the Middle East and has spread to other countries in Europe, North Africa, North America and Asia. As of November 2017, MERS-CoV had infected at least 2102 people with a fatality rate of about 35% globally, and hence there is an urgent need to identify antiviral drugs that are active against MERS-CoV. Here we show that a clinically available alcohol-aversive drug, disulfiram, can inhibit the papain-like proteases (PL(pro)s) of MERS-CoV and SARS-CoV. Our findings suggest that disulfiram acts as an allosteric inhibitor of MERS-CoV PL(pro) but as a competitive (or mixed) inhibitor of SARS-CoV PL(pro). The phenomenon of slow-binding inhibition and the irrecoverability of enzyme activity after removing unbound disulfiram indicate covalent inactivation of SARS-CoV PL(pro) by disulfiram, while synergistic inhibition of MERS-CoV PL(pro) by disulfiram and 6-thioguanine or mycophenolic acid implies the potential for combination treatments using these three clinically available drugs.

    Search related documents:
    Co phrase search for related documents
    • absence presence and active site: 1, 2, 3, 4, 5, 6, 7, 8
    • absence presence and active site near: 1
    • absence presence and acute sars respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • absence presence and lysis buffer: 1, 2, 3, 4, 5
    • activation test and acute sars respiratory syndrome: 1, 2
    • active center and acute sars respiratory syndrome: 1, 2, 3
    • active site and acute sars respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active site cysteine and acute sars respiratory syndrome: 1, 2, 3, 4, 5, 6, 7
    • active site near and acute sars respiratory syndrome: 1, 2
    • acute sars respiratory syndrome and lysis buffer: 1, 2, 3